An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis

Leukemia

Volumn 26, Issue 5, 2012, Pages 951-958

  Teodosio, C ^a   Garcia Montero A C ^a   Jara Acevedo, M ^a   Alvarez Twose I ^b   Sanchez Muoz L ^b   Almeida, J ^a   Morgado, J M ^b   Matito, A ^b   Escribano, L ^b   Orfao, A ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b HOSPITAL VIRGEN DE LA SALUD   (Spain)

Author keywords

D816V; flow cytometry; immunophenotype; KIT; mastocytosis

Indexed keywords

CD45 ANTIGEN; GROWTH FACTOR RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; STEM CELL GROWTH FACTOR RECEPTOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW CELL; BONE MARROW MAST CELL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE MUTATION; HEMATOPOIESIS; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MAST CELL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC MASTOCYTOSIS;

ALGORITHMS; BONE MARROW CELLS; CELL LINEAGE; CLUSTER ANALYSIS; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; MUTATION; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 84860739874     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.293     Document Type: Article

References (22)

1. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25: 603-625.
2. Horny HP MD, Bennett JM, Bain BJ, Akin C, Escribano L, Valent P. Mastocytosis World Health Organization (WHO) classification of tumours pathology and genetics of tumours of haematopoietic and lymphoid tissues. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). World Health Organization (WHO) Classification of Tumours Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn, vol. 2. International Agency for Research on Cancer (IARC): Lyon, France, 2008, pp 54-63.
3. Bonadonna P, Perbellini O, Passalacqua G, Caruso B, Colarossi S, Dal Fior D et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009; 123: 680-686.
4. Akin C, Scott LM, Kocabas CN, Kushnir-Sukhov N, Brittain E, Noel P et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with 'idiopathic' anaphylaxis. Blood 2007; 110: 2331-2333.
5. Alvarez-Twose I, Gonzalez de Olano D, Sanchez-Munoz L, Matito A, Esteban-Lopez MI, Vega A et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol 2010; 125: 1269-1278.
6. Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004; 103: 3222-3225.
7. Jara-Acevedo M, Garcia-Montero AC, Teodosio C, Escribano L, Alvarez I, Sanchez-Munoz L et al. Well-differentiated systemic mastocytosis (WDSM): a novel form of mastocytosis. Haematologica 2008; 93 (abstract [0226]): 91.
8. Akin C, Escribano L, Núñ ez R, García-Montero A, Angulo M, Orfao A et al. Welldifferentiated systemic mastocytosis: a new disease variant with mature mast cell phenotype and lack of codon 816 c-Kit mutations. J Allergy Clin Immunol 2004; 113 (abstract [1211]): S327.
9. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006; 108: 2366-2372.
10. Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009; 113: 5727-5736.
11. Schernthaner GH, Hauswirth AW, Baghestanian M, Agis H, Ghannadan M, Worda C et al. Detection of differentiation-and activation-linked cell surface antigens on cultured mast cell progenitors. Allergy 2005; 60: 1248-1255.
12. Matarraz S, Lopez A, Barrena S, Fernandez C, Jensen E, Flores J et al. The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia 2008; 22: 1175-1183.
13. +/Fc epsilon RI-cell population. Blood 1994; 84: 2489-2496.
14. Teodosio C, Garcia-Montero AC, Jara-Acevedo M, Sanchez-Munoz L, Alvarez-Twose I, Nunez R et al. Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol 2010; 125: 719-726, 26 e1-26 e4.
15. Escribano L, Alvarez-Twose I, Sanchez-Munoz L, Garcia-Montero A, Nunez R, Almeida J et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the spanish network on mastocytosis in a series of 145 patients. J Allergy Clin Immunol 2009; 124: 514-521.
16. Escribano L, Navalon R, Nunez R, Diaz Agustin B, Bravo P. Immunophenotypic analysis of human mast cells by flow cytometry. Curr Protoc Cytom 2001, 6.6.1-6.6.18.
17. Escribano L, Diaz-Agustin B, Lopez A, Nunez Lopez R, Garcia-Montero A, Almeida J et al. Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). Cytometry B Clin Cytom 2004; 58: 1-8.
18. Valent P, Schernthaner GH, Sperr WR, Fritsch G, Agis H, Willheim M et al. Variable expression of activation-linked surface antigens on human mast cells in health and disease. Immunol Rev 2001; 179: 74-81.
19. Furuno T, Teshima R, Kitani S, Sawada J, Nakanishi M. Surface expression of CD63 antigen (AD1 antigen) in P815 mastocytoma cells by transfected IgE receptors. Biochem Biophys Res Commun 1996; 219: 740-744.
20. Orfao A, Garcia-Montero AC, Sanchez L, Escribano L. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 2007; 138: 12-30.
21. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 2009; 41: 455-459.
22. Kilpivaara O, Levine RL. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia 2008; 22: 1813-1817.